HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells.

Abstract
The effects of cilostazol, a dual inhibitor of type 3 phosphodiesterase and adenosine uptake, on ion currents were investigated in pituitary GH(3) cells and pheochromocytoma PC12 cells. In whole-cell configuration, cilostazol (10 microm) reversibly increased the amplitude of Ca(2+)-activated K(+) current [I(K(Ca))]. Cilostazol-induced increase in I(K(Ca)) was suppressed by paxilline (1 microM) but not glibenclamide (10 microm), dequalinium dichloride (10 microM), or beta-bungarotoxin (200 nM). Pretreatment of adenosine deaminase (1 U/ml) or alpha,beta-methylene-ADP (100 microM) for 5 h did not alter the magnitude of cilostazol-stimulated I(K(Ca)). Cilostazol (30 microM) slightly suppressed voltage-dependent l-type Ca(2+) current. In inside-out configuration, bath application of cilostazol (10 microM) into intracellular surface caused no change in single-channel conductance; however, it did increase the activity of large-conductance Ca(2+)-activated K(+) (BK(Ca)) channels. Cilostazol enhanced the channel activity in a concentration-dependent manner with an EC(50) value of 3.5 microM. Cilostazol (10 microM) shifted the activation curve of BK(Ca) channels to less positive membrane potentials. Changes in the kinetic behavior of BK(Ca) channels caused by cilostazol were related to an increase in mean open time and a decrease in mean closed time. Under current-clamp configuration, cilostazol decreased the firing frequency of action potentials. In pheochromocytoma PC12 cells, cilostazol (10 microM) also increased BK(Ca) channel activity. Cilostazol-mediated stimulation of I(K(Ca)) appeared to be not linked to its inhibition of adenosine uptake or phosphodiesterase. The channel-stimulating properties of cilostazol may, at least in part, contribute to the underlying mechanisms by which it affects neuroendocrine function.
AuthorsSheng-Nan Wu, Shiuh-Inn Liu, Mei-Han Huang
JournalEndocrinology (Endocrinology) Vol. 145 Issue 3 Pg. 1175-84 (Mar 2004) ISSN: 0013-7227 [Print] United States
PMID14645120 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Calcium Channels, L-Type
  • Enzyme Inhibitors
  • Large-Conductance Calcium-Activated Potassium Channels
  • Phosphodiesterase Inhibitors
  • Potassium Channels, Calcium-Activated
  • Tetrazoles
  • alpha,beta-methyleneadenosine 5'-diphosphate
  • Adenosine Diphosphate
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Adenosine
  • Cilostazol
Topics
  • 3',5'-Cyclic-AMP Phosphodiesterases (antagonists & inhibitors)
  • Action Potentials (drug effects)
  • Adenoma
  • Adenosine (metabolism)
  • Adenosine Diphosphate (analogs & derivatives, pharmacology)
  • Animals
  • Calcium Channels, L-Type (metabolism)
  • Cilostazol
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Electric Conductivity
  • Enzyme Inhibitors (pharmacology)
  • Kinetics
  • Large-Conductance Calcium-Activated Potassium Channels
  • PC12 Cells
  • Phosphodiesterase Inhibitors (pharmacology)
  • Pituitary Gland, Anterior (cytology, metabolism)
  • Pituitary Neoplasms
  • Potassium Channels, Calcium-Activated (metabolism)
  • Rats
  • Tetrazoles (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: